RSS Feeds
Treatment of the Hypereosinophilic Syndrome with Interferon-α
- Joseph H. Butterfield, MD; and
- Gerald J. Gleich, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
We read with interest the letter by Papo and colleagues. Although it is difficult to make a generalization on the basis of a brief case report, we hesitate to call their experience a clinical failure because of the apparent low dose of interferon-α used (5 MU three times a week). In our experience, the dose of interferon-α necessary for initial control of the hypereosinophilic syndrome has been as high as 8 MU/d. This dose can often subsequently be decreased. Among many patients in our study, we noted a wide dose range that was initially necessary for control of eosinophilia. We emphasize the importance of tailoring each recipient's dose and stress that a daily dose of interferon-α may be necessary to control eosinophilia.
Joseph H. Butterfield, MD
Gerald J. Gleich, MD
Mayo Clinic and Foundation; Rochester, MN 55905
- Copyright ©2004 by the American College of Physicians
